<DOC>
	<DOCNO>NCT02131012</DOCNO>
	<brief_summary>Intraocular delivery celecoxib effective mean treat inflammation macular edema prevent structural complication vision loss patient chronic inflammation macular edema unable tolerate corticosteroid due side effect .</brief_summary>
	<brief_title>Intravitreal Celecoxib Chronic Uveitis</brief_title>
	<detailed_description>Specific Aims I : Test safety intraocular injection 1mg 4mg celecoxib patient chronic inflammation macular edema unable tolerate corticosteroid due side effect . II : Test efficacy intraocular 1mg 4mg celecoxib treat inflammation structural complication inflammation ( macular edema ) patient unable tolerate corticosteroid due side effect . After investigational new drug application Vanderbilt Institutional Review Board approval , celecoxib compound Investigational Drug Service Vanderbilt Medical Center package individual sterile single use syrinx intraocular injection within 2 hour preparation . Pharmaceutical grade celecoxib obtain drug manufacturer ( Pfizer ) certificate analysis compound sterile dimethyl sulfoxide follow strict sterile technique .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Chronic inflammation and/or macular edema despite maximal medical treatment Unable tolerate corticosteroid due side effect Aphakic Pseudophakic subject 15 year younger Have active ocular infection Pregnancy Phakic subject</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Macular edema</keyword>
</DOC>